Advisors Llc Orbi Med Capit... Net Worth

The estimated Net Worth of Advisors Llc Orbi Med Capit... is at least $239 Milión dollars as of 29 September 2017. Advisors Capit owns over 672,000 units of Otonomy Inc stock worth over $317,982 and over the last 12 years Advisors sold OTIC stock worth over $238,367,656.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Advisors Capit OTIC stock SEC Form 4 insiders trading

Advisors has made over 17 trades of the Otonomy Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Advisors sold 672,000 units of OTIC stock worth $18,984,000 on 29 September 2017.

The largest trade Advisors's ever made was selling 672,000 units of Otonomy Inc stock on 29 September 2017 worth over $18,984,000. On average, Advisors trades about 113,657 units every 70 days since 2012. As of 29 September 2017 Advisors still owns at least 4,129,638 units of Otonomy Inc stock.

You can see the complete history of Advisors Capit stock trades at the bottom of the page.

Insiders trading at Otonomy Inc

Over the last 10 years, insiders at Otonomy Inc have traded over $30,282,796 worth of Otonomy Inc stock and bought 755,065 units worth $12,114,945 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Holdings A/S Novo a Brian H Dovey. On average, Otonomy Inc executives and independent directors trade stock every 66 days with the average trade being worth of $7,317. The most recent stock trade was executed by Vickie L Capps on 28 November 2022, trading 42,242 units of OTIC stock currently worth $4,224.

What does Otonomy Inc do?

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.

Complete history of Advisors Capit stock trades at Intercept Pharmaceuticals Inc, Mirati Therapeutics Inc a Otonomy Inc

Otonomy Inc executives and stock owners

Otonomy Inc executives and other stock owners filed with the SEC include:

• David Weber,
  President, Chief Executive Officer, Director
• Dr. David Allen Weber,
  Pres, CEO & Director
• Paul Cayer,
  Chief Financial and Business Officer
• Robert Savel,
  Chief Technical Officer
• Paul E. Cayer,
  Chief Financial & Bus. Officer
• Robert Michael Savel II,
  Chief Technical Officer
• Jay Lichter,
  Independent Chairman of the Board
• Vickie Capps,
  Independent Director
• Iain McGill,
  Independent Director
• James Breitmeyer,
  Independent Director
• Theodore Schroeder,
  Independent Director
• Dr. Jay B. Lichter Ph.D.,
  Co-Founder & Independent Chairman
• Ciara Kennedy,
  Independent Director
• James Branch CPA,
  VP of Fin. & Controller
• David Skarinsky,
  Sr. VP of Clinical
• Breianna Bowen,
  VP of HR
• Fabrice Piu Ph.D.,
  Sr. VP of Preclinical Devel.
• Barbara M. Finn,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Alan Charles Foster Ph.D.,
  Chief Scientific Officer
• Julie D. Burgess,
  VP of Fin. & Admin.
• Dr. Rick Adam Friedman M.D., Ph.D.,
  Co-Founder and Member of the Advisory Panel
• Dr. Allen F. Ryan Ph.D.,
  Co-Founder and Member of the Advisory Panel
• Katherine Mary Bishop,
  Chief Scientific Officer
• Eric J Loumeau,
  GC & Chief Compliance Officer
• Carl Le Bel,
  Chief Scientific Officer
• Heather Preston,
  Director
• George J Morrow,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Chau Quang Khuong,
  Director
• Anthony J Yost,
  Chief Commercial Officer
• Dean Hakanson,
  Chief Medical Officer
• John P Mckearn,
  Director
• Partners Viii, L.P.Blair Ja...,
  
• Ventures Viii Lp Avalon Ven...,
  
• Holdings A/S Novo,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Viii Associates, L.P.Domain...,
  
• Alan Charles Foster,
  Chief Scientific Officer
• Brian H Dovey,
  Director
• Jill Marie Broadfoot,
  Director